Samsung Biologics Launches Innovative Drug Screening Services with Organoids
On June 15, 2025, Samsung Biologics, known for its role as a leading contract development and manufacturing organization (CDMO), unveiled its latest offering: Samsung Organoids. This new service aims to revolutionize drug discovery by utilizing advanced drug screening techniques that closely replicate human organ functions.
Organoids are essentially three-dimensional cell cultures that closely mimic the architecture and function of actual human organs. These innovative models provide critical insights into how potential drug compounds interact with human tissues. By leveraging these organoids, researchers can gain a deeper understanding of specific drug responses, which is essential for improving the lead selection process in drug development.
One of the standout features of Samsung Organoids is their ability to support precision screening. This capability allows researchers to predict patient responses to drug candidates more accurately, facilitating faster and more efficient preclinical development. The goal is to streamline the timeline for filing Investigational New Drug (IND) applications by employing rigorous, data-driven analyses of candidate molecules.
With the introduction of Samsung Organoids, Samsung Biologics is not only expanding its service offerings but is entering the realm of preclinical research. This expansion is significant as it encompasses various service aspects, including target discovery, lead selection, preclinical development, and clinical trial planning. The company's extensive experience in development and manufacturing means that clients can expect a high level of expertise, coupled with multi-dimensional insights into the characteristics and mechanisms of drug candidates.
Challenges are commonplace in the drug discovery phase, and Samsung Biologics is well-positioned to help clients navigate these hurdles. The company aims to enhance clinical success rates significantly, reflecting its unwavering commitment to innovation and advancing personalized medicine. "The launch of our latest service illustrates our dedication to driving innovation while enhancing drug success rates and creating new possibilities in personalized medicine," stated John Rim, CEO and President of Samsung Biologics. "By adding research services, we are poised to create added value for our clients and support the entire drug life cycle through comprehensive therapeutic analysis."
For those unfamiliar with Samsung Biologics, it operates as a CDMO that provides integrated services from the late discovery phases of drug development through to commercial manufacturing. With a capacity of 784 kL distributed across five biomanufacturing plants, Samsung Biologics leverages cutting-edge technologies to facilitate the development of diverse therapeutic modalities, including multispecific antibodies, fusion proteins, and mRNA therapeutics.
Globally, Samsung Biologics maintains a robust network, with facilities and offices in South Korea, the United States, and Japan. Its presence in these key markets enables it to effectively support clients in the U.S., Europe, and the broader APAC region. The commitment to operational excellence and quality has positioned Samsung Biologics as a reliable partner for companies navigating the complexities of drug development.
The introduction of Samsung Organoids represents a pivotal moment for the company as it continues to explore new capabilities and technologies. By fostering a focus on sustainability and societal health, Samsung Biologics not only aims to deliver high-quality products promptly but also strives to make significant contributions to global health advancements. Interested parties can find further information about these innovative drug screening services by visiting their website: https://samsungbiologics.com/
Organoids are essentially three-dimensional cell cultures that closely mimic the architecture and function of actual human organs. These innovative models provide critical insights into how potential drug compounds interact with human tissues. By leveraging these organoids, researchers can gain a deeper understanding of specific drug responses, which is essential for improving the lead selection process in drug development.
One of the standout features of Samsung Organoids is their ability to support precision screening. This capability allows researchers to predict patient responses to drug candidates more accurately, facilitating faster and more efficient preclinical development. The goal is to streamline the timeline for filing Investigational New Drug (IND) applications by employing rigorous, data-driven analyses of candidate molecules.
With the introduction of Samsung Organoids, Samsung Biologics is not only expanding its service offerings but is entering the realm of preclinical research. This expansion is significant as it encompasses various service aspects, including target discovery, lead selection, preclinical development, and clinical trial planning. The company's extensive experience in development and manufacturing means that clients can expect a high level of expertise, coupled with multi-dimensional insights into the characteristics and mechanisms of drug candidates.
Challenges are commonplace in the drug discovery phase, and Samsung Biologics is well-positioned to help clients navigate these hurdles. The company aims to enhance clinical success rates significantly, reflecting its unwavering commitment to innovation and advancing personalized medicine. "The launch of our latest service illustrates our dedication to driving innovation while enhancing drug success rates and creating new possibilities in personalized medicine," stated John Rim, CEO and President of Samsung Biologics. "By adding research services, we are poised to create added value for our clients and support the entire drug life cycle through comprehensive therapeutic analysis."
For those unfamiliar with Samsung Biologics, it operates as a CDMO that provides integrated services from the late discovery phases of drug development through to commercial manufacturing. With a capacity of 784 kL distributed across five biomanufacturing plants, Samsung Biologics leverages cutting-edge technologies to facilitate the development of diverse therapeutic modalities, including multispecific antibodies, fusion proteins, and mRNA therapeutics.
Globally, Samsung Biologics maintains a robust network, with facilities and offices in South Korea, the United States, and Japan. Its presence in these key markets enables it to effectively support clients in the U.S., Europe, and the broader APAC region. The commitment to operational excellence and quality has positioned Samsung Biologics as a reliable partner for companies navigating the complexities of drug development.
The introduction of Samsung Organoids represents a pivotal moment for the company as it continues to explore new capabilities and technologies. By fostering a focus on sustainability and societal health, Samsung Biologics not only aims to deliver high-quality products promptly but also strives to make significant contributions to global health advancements. Interested parties can find further information about these innovative drug screening services by visiting their website: https://samsungbiologics.com/
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.